# Fenofibrate

Drug · id `cardio:fenofibrate` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Antara

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention  

## In plain language

Fenofibrate is a fibrate, a cholesterol and triglyceride medicine taken by mouth. The US label read, for Antara capsules, lists two uses in adults, as an add-on to diet: lowering triglycerides in severe hypertriglyceridemia, and lowering raised LDL cholesterol in primary hyperlipidemia when the recommended LDL-lowering treatment cannot be used. The label also says fenofibrate did not reduce coronary heart disease illness and death in two large randomized trials of people with type 2 diabetes.

## Technical summary

RxNorm ingredient 8703; UNII U202363UOS. MeSH descriptor D011345 is Fenofibrate. RxClass lists the FDA chemical class Fibric Acids and the established pharmacologic class Peroxisome Proliferator-activated Receptor alpha Agonist; the record is filed under the class page Fibrates on that evidence. The label read is the Lupin Pharmaceuticals, Inc. label for Antara capsules, application NDA021695, effective 2025-10-01 in openFDA, the label the class page already uses. The plan row pointed at a generic label (ANDA200920); the Antara brand label replaces it. Fenofibrate tablets, delayed-release capsules and the choline fenofibrate products have other labels and labelled uses and were not read. This page records the label indications, the label's statement on coronary heart disease outcomes and the mechanism sentence only: no dose is given.

## Claims, with the population each applies to

## Context: Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules

Recipient: Adult; Population: Adults with severe hypertriglyceridemia, and adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible, as the indications section of the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with severe hypertriglyceridemia, and adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible, as the indications section of the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism (Regulator, edition The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective\_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.) <https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T20:11:53Z. Source state: Current. Version fingerprint: ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271.
     How it applies: Application number of the label read.
  2. Background: openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism (Regulator, edition The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective\_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.) <https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T20:11:53Z. Source state: Current. Version fingerprint: ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271.
     How it applies: Effective date of the label text read.
  3. Supports: openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism (Regulator, edition The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective\_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.) <https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-18T20:11:53Z. Source state: Current. Version fingerprint: ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271.
     How it applies: Label passage quoted in the research quote table (FEN-LB-04, FEN-LB-05, FEN-LB-06).
  4. Supports: openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism (Regulator, edition The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective\_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.) <https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1>
     Locator: results\[0\].description\[0\]. Retrieved 2026-11-18T20:11:53Z. Source state: Current. Version fingerprint: ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271.
     How it applies: Label passage quoted in the research quote table (FEN-LB-07).

## Connected pages

- Fenofibrate belongs to the fibric acids (FDA chemical class in RxClass) and is a PPAR alpha agonist: Fibrates (`cardio:fibrates`)
- FDA label lists reducing triglycerides in adults with severe hypertriglyceridemia as an indication: High triglycerides (`cardio:hypertriglyceridemia`) [a claim, not a settled fact; see claim `cardio:claim-fda-fenofibrate-label-indications` and its context]
- FDA label lists reducing elevated LDL-C in adults with primary hyperlipidemia, when recommended LDL-C lowering therapy cannot be used, as an indication: Dyslipidemia (`cardio:dyslipidemia`) [a claim, not a settled fact; see claim `cardio:claim-fda-fenofibrate-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 785a4fd9ad4dfee9413cc37105a5310476aa666164bfa9777fa03058d7d3c14f
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
